[Analysis of the diagnostic performance of MRI Liver Imaging Reporting and Data System version 2018 for intrahepatic parenchymal substantial lesions ≤3.0 cm]

Zhonghua Gan Zang Bing Za Zhi. 2022 Nov 20;30(11):1211-1217. doi: 10.3760/cma.j.cn501113-20210219-00086.
[Article in Chinese]

Abstract

Objective: To investigate the diagnostic performance of MRI Liver Imaging Reporting and Data System version 2018 in high-risk hepatocellular carcinoma (HCC) patients with intrahepatic parenchymal substantial lesions ≤3.0 cm. Methods: A retrospective analysis was conducted in hospitals between September 2014 to April 2020. 131 pathologically confirmed non-HCC cases with lesions ≤3.0 cm in diameter were randomly matched with 131 cases with lesions ≤3.0 cm in diameter and divided into benign (56 cases), other hepatic malignant tumor (OM, 75 cases), and HCC group (131 cases) in a 1:1 ratio. MRI features of the lesions were analyzed and classified according to LI-RADS v2018 criteria (tie-break rule was applied to lesions with both HCC and LR-M features). Taking the pathological results as the gold standard, the sensitivity and specificity of the LI-RADS v2018 classification criteria and the more stringent LR-5 criteria (with three main signs of HCC at the same time) were calculated for HCC, OM or benign lesions diagnosis. Mann -Whitney U test was used to compare the classification results. Results: The number of cases classified as LR-M, LR-1, LR-2, LR-3, LR-4, and LR-5 in HCC group after applying the tie-break rule were 14, 0, 0, 12, 28, and 77, respectively. There were 40, 0, 0, 4, 17, 14 and 8, 5, 1, 26, 13, 3 cases in benign and OM group, respectively. There were 41 (41/77), 4 (4/14) and 1 (1/3) lesion case in the HCC, OM and benign group, respectively, that met the more stringent LR-5 criteria. The sensitivity of LR-4 combined with LR-5 (LR-4/5) criteria, LR-5 criteria and more stringent LR-5 criteria for HCC diagnosis were 80.2% (105/131), 58.8% (77/131) and 31.3% (41/131), respectively, and the specificity were 64.1% (84/131), 87.0% (114/131) and 96.2% (126/131), respectively. The sensitivity and specificity of LR-M were 53.3% (40/75) and 88.2% (165/187), respectively. The sensitivity and specificity using LR-1 combined with LR-2 (LR-1/2) criteria for the diagnosis of benign liver lesions were 10.7% (6/56) and 100% (206/206), respectively. Conclusions: LR-1/2, LR-5, and LR-M criteria have high diagnostic specificity for intrahepatic lesions with a diameter of ≤3.0 cm. Lesions classified as LR-3 are more likely to be benign. The specificity of LR-4/5 criteria is low, while the more stringent LR-5 criteria has a high specificity for HCC diagnosis.

目的: 探讨2018版MRI肝脏影像报告和数据系统(LI-RADS v2018)对肝细胞癌(HCC)高危风险患者肝内≤3.0 cm实质性病变的诊断效能。 方法: 回顾性分析2014年9月至2020年4月间经病理证实且病灶长径≤3.0 cm的131例非HCC病例资料,并按1∶1比例随机匹配131例病灶长径≤3.0 cm的HCC病例,分为良性组(56例)、肝脏其他恶性肿瘤(OM)组(75例)、HCC组(131例)。分析病灶的MRI征象并依据LI-RADS v2018标准对病灶进行分类(对兼有HCC征象和LR-M征象的病灶运用平局决胜规则)。以病理结果为金标准,计算LI-RADS v2018分类标准和更严格的LR-5标准(同时具备3个HCC主要征象)对诊断HCC、OM或良性病变的灵敏度、特异度。分类结果的比较采用Mann-Whitney U检验。 结果: 应用平局决胜规则后HCC组归类为LR-M、LR-1、LR-2、LR-3、LR-4、LR-5的例数分别为14、0、0、12、28、77例,OM组分别为40、0、0、4、17、14例,良性组分别为8、5、1、26、13、3例;HCC组、OM组、良性组归为LR-5的病灶中符合更严格LR-5标准的例数分别为41例(41/77)、4例(4/14)、1例(1/3);以LR-4联合LR-5(LR-4/5)标准、LR-5标准、“更严格的LR-5标准”诊断HCC的灵敏度分别为80.2%(105/131)、58.8%(77/131)、31.3%(41/131),特异度分别为64.1%(84/131)、87.0%(114/131)、96.2%(126/131);以LR-M标准诊断OM的灵敏度为53.3%(40/75)、特异度为88.2%(165/187);以LR-1联合LR-2(LR-1/2)标准诊断肝良性病变的灵敏度为10.7%(6/56)、特异度为100%(206/206)。 结论: 对肝内长径≤3.0 cm的病灶,LR-1/2、LR-5、LR-M标准相应的诊断特异度均较高;归类为LR-3的病灶更可能是良性病变;以LR-4/5标准诊断HCC的特异度低;更严格的LR-5标准对诊断HCC具有更高的特异度。.

Publication types

  • English Abstract

MeSH terms

  • Carcinoma, Hepatocellular* / diagnostic imaging
  • Contrast Media
  • Humans
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / pathology
  • Magnetic Resonance Imaging / methods
  • Retrospective Studies
  • Sensitivity and Specificity

Substances

  • Contrast Media